Top Markets
Coin of the day
Caladrius Biosciences, Inc. Caladrius Biosciences, Inc.

Caladrius Biosciences, Inc.

CLBS
Rangering i aksjer #33300
Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical... Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical company primarily engaged in the development and commercialization of cellular therapies. These therapies aim to either reverse various diseases or stimulate the regeneration of compromised tissue. The company's pipeline includes several key investigational therapies: HONEDRA, which has received the prestigious SAKIGAKE designation, is undergoing Phase II clinical trials as a potential treatment for critical limb ischemia; XOWNA is currently in Phase IIb trials targeting coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy, is being evaluated for chronic kidney disease in patients prior to requiring dialysis. Previously known as NeoStem, Inc., the firm adopted its current name, Caladrius Biosciences, Inc., in June 2015. Established in 1980, the company maintains its corporate headquarters in Basking Ridge, New Jersey.
Aksjekurs
$0.4264
Sist synkronisert: 2022-09-14
Markedsverdi
$7.93M
Endring (1 dag)
-16.44%
Endring (1 år)
0.00%
Land
US
Handel Caladrius Biosciences, Inc. (CLBS)

Kategori

Aksjeprishistorikk for Caladrius Biosciences, Inc. (CLBS)
Høyeste sluttskurs: $0.50 den 2022-09-01

Laveste sluttskurs: $20.36 den 2015-06-01
Aksjeprishistorikk for Caladrius Biosciences, Inc. fra 2015 til 2026
Årlig aksjeprisytelse
År Ytelse
2022 -43.51%
2021 -42.36%
2020 -36.52%
2019 -44.38%
2018 26.20%
2017 2.72%
2016 -70.04%
2015 0.00%
Aksjepris for lignende selskaper eller konkurrenter
Selskap Aksjepris Endring 1år% Land
$511.97 30.34%
US
$984.83 50.62%
NL
$736.38 7.15%
CH
$1.07K -6.40%
KR
$255.62 13.43%
BE